Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Outstanding Scientific Achievement Award Lecture 2011: Defeating Diabesity
Matthias H. Tschöp, Richard D. DiMarchi
Diabetes (2012) Vol. 61, Iss. 6, pp. 1309-1314
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Steven E. Kahn, Mark E. Cooper, Stefano Del Prato
The Lancet (2013) Vol. 383, Iss. 9922, pp. 1068-1083
Open Access | Times Cited: 1552
Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action
Jonathan E. Campbell, Daniel J. Drucker
Cell Metabolism (2013) Vol. 17, Iss. 6, pp. 819-837
Open Access | Times Cited: 1283
Islet α cells and glucagon—critical regulators of energy homeostasis
Jonathan E. Campbell, Daniel J. Drucker
Nature Reviews Endocrinology (2015) Vol. 11, Iss. 6, pp. 329-338
Closed Access | Times Cited: 244
Emerging combinatorial hormone therapies for the treatment of obesity and T2DM
Sharon Sadry, Daniel J. Drucker
Nature Reviews Endocrinology (2013) Vol. 9, Iss. 7, pp. 425-433
Closed Access | Times Cited: 168
The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications
Sten Madsbad
Diabetes Obesity and Metabolism (2013) Vol. 16, Iss. 1, pp. 9-21
Closed Access | Times Cited: 135
GLP-1 based therapeutics: simultaneously combating T2DM and obesity
Kristy M. Heppner, Diego Pérez–Tilve
Frontiers in Neuroscience (2015) Vol. 9
Open Access | Times Cited: 108
Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice
Sigrid Jall, Stephan Sachs, Christoffer Clemmensen, et al.
Molecular Metabolism (2017) Vol. 6, Iss. 5, pp. 440-446
Open Access | Times Cited: 97
Structural and Pharmacological Characterization of Novel Potent and Selective Monoclonal Antibody Antagonists of Glucose-dependent Insulinotropic Polypeptide Receptor
Peter Ravn, Chaithanya Madhurantakam, Susan Kunze, et al.
Journal of Biological Chemistry (2013) Vol. 288, Iss. 27, pp. 19760-19772
Open Access | Times Cited: 81
The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes
Yan‐Ling He, William G. Haynes, Charles D. Meyers, et al.
Diabetes Obesity and Metabolism (2019) Vol. 21, Iss. 6, pp. 1311-1321
Closed Access | Times Cited: 72
Gastric inhibitory polypeptide immunoneutralization attenuates development of obesity in mice
Michael O. Boylan, Patricia A. Glazebrook, Milos Tatalovic, et al.
AJP Endocrinology and Metabolism (2015) Vol. 309, Iss. 12, pp. E1008-E1018
Open Access | Times Cited: 60
Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction
Safina Ali, John R. Ussher, Laurie L. Baggio, et al.
Molecular Metabolism (2014) Vol. 4, Iss. 2, pp. 132-143
Open Access | Times Cited: 60
Diabetes and obesity treatment based on dual incretin receptor activation: ‘twincretins’
Marius Skow, Natasha C. Bergmann, Filip K. Knop
Diabetes Obesity and Metabolism (2016) Vol. 18, Iss. 9, pp. 847-854
Closed Access | Times Cited: 55
A link between hepatic glucose production and peripheral energy metabolism via hepatokines
Aya Abdul-Wahed, Amandine Gautier‐Stein, S. Casteras, et al.
Molecular Metabolism (2014) Vol. 3, Iss. 5, pp. 531-543
Open Access | Times Cited: 54
Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice
Varun Pathak, Victor A. Gault, Peter R. Flatt, et al.
Molecular and Cellular Endocrinology (2014) Vol. 401, pp. 120-129
Closed Access | Times Cited: 45
The hidden role of NLRP3 inflammasome in obesity‐related COVID‐19 exacerbations: Lessons for drug repurposing
Ilaria Bertocchi, Federica Foglietta, Debora Collotta, et al.
British Journal of Pharmacology (2020) Vol. 177, Iss. 21, pp. 4921-4930
Open Access | Times Cited: 34
Seeking satiety: From signals to solutions
Matthias H. Tschöp, Jeffrey M. Friedman
Science Translational Medicine (2023) Vol. 15, Iss. 723
Closed Access | Times Cited: 12
Reversal of the deleterious effects of chronic dietary HFCS-55 intake by PPAR-δ agonism correlates with impaired NLRP3 inflammasome activation
Massimo Collino, Elisa Benetti, Mara Rogazzo, et al.
Biochemical Pharmacology (2012) Vol. 85, Iss. 2, pp. 257-264
Open Access | Times Cited: 46
A β-Peptide Agonist of the GLP-1 Receptor, a Class B GPCR
Elizabeth V. Denton, Cody J. Craig, Rebecca L. Pongratz, et al.
Organic Letters (2013) Vol. 15, Iss. 20, pp. 5318-5321
Open Access | Times Cited: 39
Peripheral targets in obesity treatment: a comprehensive update
Antonios Chatzigeorgiou, Eleni Kandaraki, Athanasios G. Papavassiliou, et al.
Obesity Reviews (2014) Vol. 15, Iss. 6, pp. 487-503
Open Access | Times Cited: 37
Antiobesity and antihyperglycaemic effects of Adiantum capillus-veneris extracts: in vitro and in vivo evaluations
Violet Kasabri, Entisar K. Al-Hallaq, Yasser Bustanji, et al.
Pharmaceutical Biology (2016) Vol. 55, Iss. 1, pp. 164-172
Open Access | Times Cited: 36
TRC210258, a novel TGR5 agonist, reduces glycemic and dyslipidemic cardiovascular risk in animal models of diabesity
Shitalkumar Zambad, Davinder Tuli, A Matur, et al.
Diabetes Metabolic Syndrome and Obesity (2013), pp. 1-1
Open Access | Times Cited: 29
GUB06‐046, a novel secretin/glucagon‐like peptide 1 co‐agonist, decreases food intake, improves glycemic control, and preserves beta cell mass in diabetic mice
Søren B. van Witteloostuijn, Louise S. Dalbøge, Gitte Hansen, et al.
Journal of Peptide Science (2017) Vol. 23, Iss. 12, pp. 845-854
Closed Access | Times Cited: 24
Bifunctional PEGylated Exenatide-Amylinomimetic Hybrids to Treat Metabolic Disorders: An Example of Long-Acting Dual Hormonal Therapeutics
Chengzao Sun, James L. Trevaskis, Carolyn M. Jodka, et al.
Journal of Medicinal Chemistry (2013) Vol. 56, Iss. 22, pp. 9328-9341
Closed Access | Times Cited: 19
Phytochemical and biological evaluations of Arum hygrophilum boiss. (Araceae)
Fatma U. Afifi, Violet Kasabri, Simona Carmen Lițescu, et al.
Pharmacognosy Magazine (2017) Vol. 13, Iss. 50, pp. 275-275
Open Access | Times Cited: 14
Chemical Composition and In vitro Studies of the Essential Oil and Aqueous Extract of Pelargonium graveolens Growing in Jordan for Hypoglycaemic and Hypolipidemic Properties
Fatma U. Afifi
European Journal of Medicinal Plants (2014) Vol. 4, Iss. 2, pp. 220-233
Closed Access | Times Cited: 10
Page 1 - Next Page

Scroll to top